Osteoarthritis (OA) of the KneeNCT07637682
Percutaneous Neurostimulation in Knee Osteoarthritis
A study testing nerve stimulation using a nerve stimulator to the genicular nerve and nerve stimulation using a nerve stimulator to the saphenous nerve in people with Osteoarthritis (OA) of the Knee and Neuromodulation, run by Tanta University at 1 site in Egypt.
Trial summary
Peripheral nerve stimulation (PNS) is a drug-free pain management procedure that uses electrical impulses to target specific nerves and block pain signals. PNS helps decrease perception of pain, providing real answers to patients dealing with chronic knee pain. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Osteoarthritis (OA) of the Knee, Neuromodulation
- What is being tested?
- nerve stimulation using a nerve stimulator to the genicular nerve and nerve stimulation using a nerve stimulator to the saphenous nerve
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 2 Jun 2026to Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- adults between the ages of 30 and 70 years with a clinical diagnosis of moderate to severe knee OA who suffered knee pain.
- Patients who cannot afford intra-articular injections or radiofrequency ablation (RFA).
- patients who had failed 2 different oral pain medications and 6 weeks of physical therapy.
Who cannot join
- Patients with OA show improvement in pain after physiotherapy.
- patients evaluated by an orthopaedic surgeon and deemed to be surgical candidates due to knee pathologies other than OA.
- pregnant patients.
- patients on anticoagulation therapy, who were not permitted to stop anticoagulation.
- patients with previous trauma, neurological or endocrine diseases like diabetes mellitus, and knee tumors; and patients with inflammatory arthritis.
- people who had received an intra-articular knee injection within the last 6 months.
- Patients with tendon tears, bursitis, or calcified tendonitis as proven by imaging.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Faculty of medicine, Tanta University
Tanta
Aliaa Mamdouh Abdelaziz Farag, MD, +201069468486, aliaa.mamdouh@med.tanta.edu.eg
About this study
Official title: Percutaneous Peripheral Temporary Neurostimulation in Moderate to Severe Knee Osteoarthritis
Peripheral nerve stimulation (PNS) is a drug-free pain management procedure that uses electrical impulses to target specific nerves and block pain signals. PNS helps decrease perception of pain, providing real answers to patients dealing with chronic knee pain. The case study discussed in this presentation is of the use of PNS targeting the superior lateral genicular nerve and the saphenous nerve for a patient with moderate to severe knee pain from osteoarthritis
- Conditions
- Osteoarthritis (OA) of the Knee, Neuromodulation
- Being tested
- nerve stimulation using a nerve stimulator to the genicular nerve, nerve stimulation using a nerve stimulator to the saphenous nerve
- Medical subject headings
- Osteoarthritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
nerve stimulation using a nerve stimulator to the genicular nerveDevice
temporary transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes.
nerve stimulation using a nerve stimulator to the saphenous nerveDevice
temporary transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes.
| Study group | Role | What they receive |
|---|---|---|
| transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve block | Experimental | Not described Receives: Device: nerve stimulation using a nerve stimulator to the genicular nerve |
| transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve | Experimental | Not described Receives: Device: nerve stimulation using a nerve stimulator to the saphenous nerve |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in visual analogue scale after intervention.
Decrement (clinical improvement) in visual analogue scale (VAS) immediately after intervention. The participant's knee discomfort was measured using a VAS. Participants were asked to score their level of pain on a 100-mm horizontal line, ranging from 0 to 100.
Measured: immediately after intervention.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jun 2026
- Study start2 Jun 2026
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Osteoarthritis (OA) of the KneeStudies of the same condition, open and under way.
- More trials run by Tanta UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aliaa Mamdouh Abdelaziz Farag, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07637682
- Sponsor's protocol ID
- 36265PR60/5/26
- Status last verified
- Jun 2026
- First submitted
- 4 Jun 2026
- Last updated
- 18 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Plan to Share IPD: "Yes" Plan Description: "Data obtained through this study may be provided to qualified researchers with academic interest in scapular dyskinesis. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e., a material transfer agreement) are prerequisites to the sharing of data with the requesting party. Results will be published by the investigators in academic journal.
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Percutaneous Peripheral Temporary Neurostimulation in Moderate to Severe Knee Osteoarthritis
- ClinicalTrials.gov ID
- NCT07637682
- Acronym / sponsor ID
- 36265PR60/5/26
- Conditions
- Osteoarthritis (OA) of the Knee, Neuromodulation
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 2 Jun 2026 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 10 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Peripheral nerve stimulation (PNS) is a drug-free pain management procedure that uses electrical impulses to target specific nerves and block pain signals. PNS helps decrease perception of pain, providing real answers to patients dealing with chronic knee pain. The case study discussed in this presentation is of the use of PNS targeting the superior lateral genicular nerve and the saphenous nerve for a patient with moderate to severe knee pain from osteoarthritis
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve block | Experimental | Device: nerve stimulation using a nerve stimulator to the genicular nerve |
| transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve | Experimental | Device: nerve stimulation using a nerve stimulator to the saphenous nerve |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- adults between the ages of 30 and 70 years with a clinical diagnosis of moderate to severe knee OA who suffered knee pain.
- Patients who cannot afford intra-articular injections or radiofrequency ablation (RFA).
- patients who had failed 2 different oral pain medications and 6 weeks of physical therapy.
Key exclusion criteria (7 listed)
- Patients with OA show improvement in pain after physiotherapy.
- patients evaluated by an orthopaedic surgeon and deemed to be surgical candidates due to knee pathologies other than OA.
- pregnant patients.
- patients on anticoagulation therapy, who were not permitted to stop anticoagulation.
- patients with previous trauma, neurological or endocrine diseases like diabetes mellitus, and knee tumors; and patients with inflammatory arthritis.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| nerve stimulation using a nerve stimulator to the genicular nervetemporary transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes. | Device | transcutaneous nerve stimulation using a nerve stimulator to the genicular nerve block |
| nerve stimulation using a nerve stimulator to the saphenous nervetemporary transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve, with settings 2Hz, 0.2mA, 1ms, where the nerve is stimulated for 4 to 6 minutes. | Device | transcutaneous nerve stimulation using a nerve stimulator to the saphenous nerve |
Primary outcome
Change in visual analogue scale after intervention.
Time frame: immediately after intervention.
Decrement (clinical improvement) in visual analogue scale (VAS) immediately after intervention. The participant's knee discomfort was measured using a VAS. Participants were asked to score their level of pain on a 100-mm horizontal line, ranging from 0 to 100.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2026.
- Individual participant dataSharing planned: Yes. Plan to Share IPD: "Yes" Plan Description: "Data obtained through this study may be provided to qualified researchers with academic interest in scapular dyskinesis. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e., a material transfer agreement) are prerequisites to the sharing of data with the requesting party. Results will be published by the investigators in academic journal.
Related trials for Osteoarthritis (OA) of the Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
RecruitingPhase 3
A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
Obesity, Overweight
RecruitingPhase 3
A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
Obesity, Overweight and/or Obesity
Not yet recruiting
Opioid Reduction and Enhanced Recovery in Orthopaedic Surgery (OREOS)-Knee
Knee Arthroplasty, Total, Partial Knee Arthroplasty
RecruitingPhase 2
Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis
Knee Osteoarthritis, Knee Osteoarthritis (Knee OA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing nerve stimulation using a nerve stimulator to the genicular nerve and nerve stimulation using a nerve stimulator to the saphenous nerve in people with Osteoarthritis (OA) of the Knee and Neuromodulation, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aliaa Mamdouh Abdelaziz Farag, MD (+201069468486, aliaa.mamdouh@med.tanta.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in visual analogue scale after intervention. (time frame: immediately after intervention.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026.